Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 210-036-0 | CAS number: 603-35-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: inhalation
Administrative data
- Endpoint:
- short-term repeated dose toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: acceptable test method based on scientific principles with detailed documentation, only 2 animals per dose group
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 983
- Report date:
- 1983
Materials and methods
- Principles of method if other than guideline:
- This study was conducted to assess the inhalation toxicity of the test substance when administered as a respirable aerosol in a xylene vehicle to male and female beagle dogs. Four atmospheric concentration levels and two different durations of treatment were used in the study; the specific test regimes were as follows: two dogs (1 male, 1 female) per group received twenty 6-hour exposures over four weeks at exposure levels of 0.5, 3.2. 9.7 and 28 milligrams test substance per meter cubed (mg/m3); two 6-hour exposures were administered to two dogs (1 male, l female) per group at concentrations of 0.3, 3.6 and 24 mg/m3 test substance. These shorter duration treatments were followed by a four week recovery period. A concurrent vehicle control group (1 male, 1 female dog) received twenty 6-hour exposures to150 parts per million (v/v in air) of xylene, a level of solvent which was comparable to that in each test exposure chamber. Chambers were monitored analytically for test substance levels at least 3 times/chamber/day. Particle size distribution were determined periodically throughout the study. Body weight measurements, physical observations and neurological examinations were performed pre-test and weekly throughout the study. Complete gross postmortem examinations were performed and selected sections of nervous system tissue were preserved from all test animals for histopathological evaluation.
- GLP compliance:
- not specified
- Limit test:
- no
Test material
- Reference substance name:
- Triphenylphosphine
- EC Number:
- 210-036-0
- EC Name:
- Triphenylphosphine
- Cas Number:
- 603-35-0
- Molecular formula:
- C18H15P
- IUPAC Name:
- triphenylphosphine
- Test material form:
- solid
Constituent 1
Test animals
- Species:
- dog
- Strain:
- Beagle
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- body weight 9.6-13.2 kg in males and 8.2-10.4 kg in females
Administration / exposure
- Route of administration:
- inhalation: aerosol
- Type of inhalation exposure:
- whole body
- Details on inhalation exposure:
- - Analytical concentrations of 0, 0.5, 3.2, 9.7, 28 mg/m3 (as aerosol in xylene, aerosol particles 0.5 um) or for only 2 times to 0.5, 3.2 or 28 mg/m3 (post exposure observation period 30 days).
- Whole-body exposure using chambers of 10 m3 which received an aerosol produced from the test substance dissolved in xylene (complete air change in the chamber every 3.3 minutes).
- The concentration of xylene was 150 ppm or less in all chambers (solvent not specified, isomer mixture??).
- Chambers were monitored analytically for test substance levels 3x/d per chamber and particle-size distribution periodically.
- The count medium diameter of the aerosol particles was found to be 0.5 um or less, i.e. respirable. - Analytical verification of doses or concentrations:
- yes
- Duration of treatment / exposure:
- 5 weeks
- Frequency of treatment:
- 3 - 5 days/week, 6 hours/day (20 exposures)
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0.5 mg/m³ air (nominal)
- Remarks:
- as aerosol in xylene
- Dose / conc.:
- 3.2 mg/m³ air (nominal)
- Remarks:
- as aerosol in xylene
- Dose / conc.:
- 9.7 mg/m³ air (nominal)
- Remarks:
- as aerosol in xylene
- Dose / conc.:
- 28 mg/m³ air (nominal)
- Remarks:
- as aerosol in xylene
- No. of animals per sex per dose:
- 1
- Control animals:
- yes, concurrent vehicle
Examinations
- Observations and examinations performed and frequency:
- Body weight determined once weekly. Animal observation twice daily, full physical and neurological assessment once weekly.
- Sacrifice and pathology:
- Dogs were sacrificed and necropsy performed. Histopathologic examination was focussed on the spinal cord and sciatic nerve.
- Statistics:
- no data
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- At 28 mg/m3 (20 exposures), both dogs showed indications of neurological impairment: failure in the extensor postural thrust reflex with tendency to knuckle over, unsteadiness and weakness in the hind limbs. (This effect was already noted in one male dog having received only two exposures.) The locomotor reflex in the male dog appeared also unsteady and uncoordinated (ataxia).
At 10 mg/m3 erratic placement of limbs on week 1 and 4 was observed in one male dog.
In one male receiving only 2 exposures of 3 mg/m3 some limb placement incoordination throughout the study was seen.
Only the effects at the highest dose were considered by the authors to be treatment-related (in other dose groups effects not persistent, no severe signs, animals were only exposed twice). - Mortality:
- no mortality observed
- Description (incidence):
- All animals survived.
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- Body weight development was normal.
- Neuropathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- The sections prepared from the high-dosed dogs revealed moderate generalised vacuolative degeneration of axons in the ventral and lateral funicule of both the cervical and lumbar spinal cord. No such findings in the sciatic nerve. No such lesions were noted in the control animals having received xylene alone.
The above mentioned neuronal lesions were seen in the longitudinal sections, recognised with both H&E and luxol fast blue stains, characterised by multiple dilated or vacuolated axon sheaths with accumulations of scattered eosinophilic debris and occasional dark rounded bits of what appeared to have been nuclear chromatin.
Similar damages in the lower dose groups, but marginal in nature, were not considered to correlate with test substance exposure since in a histopathological reevaluation also historical control animals showed some axonal lesions. Sporadic degeneration is an expected finding in the spinal cord of "normal" animals.
Effect levels
open allclose all
- Dose descriptor:
- NOAEC
- Effect level:
- 10 mg/m³ air
- Sex:
- male/female
- Basis for effect level:
- other: no adverse effects at this dose
- Dose descriptor:
- LOAEC
- Effect level:
- 28 mg/m³ air
- Sex:
- male/female
- Basis for effect level:
- clinical signs
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
- Executive summary:
This study was conducted to assess the inhalation toxicity of the test substance when administered as a respirable aerosol in a xylene vehicle to male and female beagle dogs.
Four atmospheric concentration levels and two different durations of treatment were used in the study; the specific test regimes were as follows: two dogs (1 male, 1 female) per group received twenty 6-hour exposures over four weeks at exposure levels of 0.5, 3.2. 9.7 and 28 milligrams test substance per meter cubed (mg/m3); two 6-hour exposures were administered to two dogs (1 male, 1 female) per group at concentrations of 0.3, 3.6 and 24 mg/m3 test substance. These shorter duration treatments were followed by a four week recovery period. A concurrent vehicle control group (1 male, 1 female dog) received twenty 6-hour exposures to 150 parts per million (v/v in air) of xylene, a level of solvent which was comparable to that in each test exposure chamber.
Chambers were monitored analytically for test substance levels at least 3 times/chamber/day. Particle size distribution were determined periodically throughout the study. Body weight measurements, physical observations and neurological examinations were performed pre-test and weekly throughout the study. Complete gross postmortem examinations were performed and selected sections of nervous system tissue were preserved from all test animals for histopathological evaluation.
All animals survived the duration of the study. Signs of neurological impairment were noted during the study in male dogs receiving 2 exposures at 24 mg/m3 test substance or 20 exposures at 28 mg/m3 test substance and in the female dogs receiving 20 exposures at 28 mg/m3test substance.
Histopathological examinations"(H&E, and luxol fast blue stains) revealed moderate generalized vacuolative degeneration of the ventral and lateral funicle of the cervical and lumbar spinal cord of the dogs which received twenty exposures to 28 mg/m3 test substance. Similar lesions, although minimal and focal in nature were noted in spinal cord sections of dogs receiving 0.5 or 3.2 mg/m3test substance. In the lowest treatment group animals, this lesion was observed in one male following 20 exposures and in·one female following only two exposures. These lesions were not seen in any vehicle control dog. Evaluations of body weight, general physical observations (non-neurological) and gross postmortem results were considered unremarkable.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.